Intelligent Bio Solutions Inc. has released its unaudited financial results for the three and nine months ended March 31, 2025. The company reported revenue of $728,867 for the three months ended March 31, 2025, down from $823,800 during the same period in 2024. For the nine months ended March 31, 2025, revenue totaled $2.209 million, compared to $2.384 million for the same period in the previous year. The company also reported a comprehensive loss of $2.435 million for the three months ended March 31, 2025, a decrease from the $3.131 million loss reported for the same period in 2024. For the nine-month period, the comprehensive loss was $7.313 million, slightly lower than the $7.482 million loss recorded in the previous year. Intelligent Bio Solutions Inc. cited selling, general, and administrative expenses of $2.408 million for the three months ended March 31, 2025, compared to $2.426 million for the same period in 2024. For the nine-month period, these expenses were $6.166 million, down from $6.588 million in the previous year. The company's gross profit for the three months ended March 31, 2025, was $341,368, up from $178,489 during the same period in 2024. For the nine months ended March 31, 2025, the gross profit was $911,282, compared to $610,068 in the previous year. Intelligent Bio Solutions Inc. noted no significant updates regarding its business operations beyond the financial results disclosed.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。